NASDAQ:OVID

Ovid Therapeutics - OVID Stock Forecast, Price & News

$1.82

+0.07 (+4.00%)

(As of 12/8/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.76
▼
$1.85
50-Day Range: $1.44
▼
$1.89
52-Week Range: $1.41
▼
$3.55

Volume: 81,099 shs
Average Volume: 149,853 shs
Market Capitalization: $128.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.50

Ovid Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 37.4% Upside
$2.50 Price Target
Short Interest: Healthy
0.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$37,290 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.79) to ($0.78) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

277th out of 1,022 stocks

Pharmaceutical Preparations Industry

113th out of 499 stocks

3.0

Analyst's Opinion

Consensus Rating
Ovid Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.50, Ovid Therapeutics has a forecasted upside of 37.4% from its current price of $1.82.
Amount of Analyst Coverage
Ovid Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.52% of the float of Ovid Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Ovid Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ovid Therapeutics has recently increased by 3.64%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Ovid Therapeutics does not currently pay a dividend.
Dividend Growth
Ovid Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ovid Therapeutics has received a 71.15% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for Epilepsy or seizures" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Ovid Therapeutics is -0.85.

1.5

News and Social Media Coverage

News Sentiment
Ovid Therapeutics has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Ovid Therapeutics this week, compared to 0 articles on an average week.
Search Interest
2 people have searched for OVID on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ovid Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,290.00 in company stock.
Percentage Held by Insiders
10.70% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
49.31% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Ovid Therapeutics are expected to grow in the coming year, from ($0.79) to ($0.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ovid Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ovid Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ovid Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ovid Therapeutics (NASDAQ:OVID) Stock

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OVID Stock News Headlines

December 2, 2022 | finance.yahoo.com

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

November 14, 2022 | finance.yahoo.com

Cancer Gene Therapy Market Report 2022: High Growth in the Pharmaceutical Industry Driving Sector

November 13, 2022 | marketwatch.com

Dravet Syndrome Therapeutics Market 2023: Global Research by Size, Share, Growth Trends, Manufacturers, and Regional Demand Scope Forecast to 2029

November 8, 2022 | finance.yahoo.com

Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

October 18, 2022 | finance.yahoo.com

Ovid Therapeutics (NASDAQ:OVID) shareholders have endured a 77% loss from investing in the stock five years ago

September 27, 2022 | finance.yahoo.com

Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

September 7, 2022 | finance.yahoo.com

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 7, 2022 | finance.yahoo.com

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 18, 2022 | seekingalpha.com

Ovid Therapeutics (OVID) Corporate Presentation - Slideshow

August 14, 2022 | finance.yahoo.com

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

August 9, 2022 | finance.yahoo.com

Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

August 2, 2022 | msn.com

Ovid-Elsie Area Schools Superintendent Ryan Cunningham is retiring Aug. 31

July 28, 2022 | bizjournals.com

The Petri Dish: FDA agrees to review Biogen's ALS drug despite failed trial

July 25, 2022 | finance.yahoo.com

Flare Therapeutics Appoints Amit Rakhit, M.D. as President and Chief Executive Officer

July 3, 2022 | seekingalpha.com

REAL,COMM and OVID among after hour movers

June 10, 2022 | finance.yahoo.com

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

June 6, 2022 | finance.yahoo.com

Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

May 11, 2022 | finance.yahoo.com

Investors in Ovid Therapeutics (NASDAQ:OVID) have unfortunately lost 80% over the last five years

May 10, 2022 | benzinga.com

Ovid Therapeutics: Q1 Earnings Insights

May 10, 2022 | finance.yahoo.com

Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

May 4, 2022 | finance.yahoo.com

3 Biotech Stocks Under $10 to Add to Your Buy List

March 21, 2022 | ca.finance.yahoo.com

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

March 15, 2022 | seekingalpha.com

Ovid Therapeutics GAAP EPS of -$0.38 misses by $0.22

March 15, 2022 | finance.yahoo.com

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results

March 7, 2022 | finance.yahoo.com

Do Institutions Own Ovid Therapeutics Inc. (NASDAQ:OVID) Shares?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OVID Company Calendar

Last Earnings: 11/08/2022
Today: 12/09/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/21/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OVID
CUSIP: N/A
CIK: 1636651
Web: www.ovidrx.com
Phone: (646) 661-7661
Fax: N/A
Employees: 57
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $2.50
High Stock Price Forecast: $2.50
Low Stock Price Forecast: $2.50
Forecasted Upside/Downside: +37.4%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.99)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $122.83 million
Net Margins: N/A
Pretax Margin: -4,736.61%
Return on Equity: -42.99%
Return on Assets: -37.73%

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 20.87
Quick Ratio: 20.87

Sales & Book Value

Annual Sales: $208.38 million
Price / Sales: 0.62
Cash Flow: $1.82 per share
Price / Cash Flow: 1.00
Book Value: $2.64 per share
Price / Book: 0.69

Miscellaneous

Outstanding Shares: 70,467,000
Free Float: 62,927,000
Market Cap: $128.25 million
Optionable: Not Optionable
Beta: 1.05

Key Executives

Dr. Jeremy Max Levin Ba Zoology (Age 69)
Dphil, Mb Bchir, Pres, CEO & Chairman
Comp: $847.07k

Mr. Jeffrey A. Rona (Age 54)
Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer
Comp: $613.18k

Mr. Thomas Michael Perone J.D. (Age 57)
M.B.A., Gen. Counsel, Chief Compliance Officer & Corp. Sec.
Comp: $632.11k

Dr. Matthew J. During DSc (Age 65)
FACP, FRACP, M.D., Ph.D., Founder & Member of Scientific Advisory Board

Mr. Jason Tardio M.B.A. (Age 45)
Chief Operating Officer

Ms. Lora Pike
Sr. Director of Investor Relations & PR

Mr. Simon D. Kelner (Age 49)
Sr. VP & Chief HR Officer

Dr. Dirk Haasner (Age 57)
Sr. VP of Global Manufacturing & CMC QA

Ms. Suzanne K. Wakamoto SHRM-SCP
SPHR, Sr. VP of Culture & Facilities

Dr. Claude Nicaise M.D. (Age 69)
Head of R&D

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OVID Stock - Frequently Asked Questions

Should I buy or sell Ovid Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OVID shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares.
View OVID analyst ratings or view top-rated stocks.
What is Ovid Therapeutics' stock price forecast for 2023?: 1 brokers have issued twelve-month target prices for Ovid Therapeutics' stock. Their OVID share price forecasts range from $2.50 to $2.50. On average, they predict the company's share price to reach $2.50 in the next year. This suggests a possible upside of 37.4% from the stock's current price.
View analysts price targets for OVID or view top-rated stocks among Wall Street analysts.
How have OVID shares performed in 2022?: Ovid Therapeutics' stock was trading at $3.21 at the beginning of the year. Since then, OVID shares have decreased by 43.3% and is now trading at $1.82.
View the best growth stocks for 2022 here.
When is Ovid Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our OVID earnings forecast.
How were Ovid Therapeutics' earnings last quarter?: Ovid Therapeutics Inc. (NASDAQ:OVID) issued its earnings results on Tuesday, November, 8th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04. The company had revenue of $0.01 million for the quarter.
What other stocks do shareholders of Ovid Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX).

When did Ovid Therapeutics IPO?: (OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.
What is Ovid Therapeutics' stock symbol?: Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."
Who are Ovid Therapeutics' major shareholders?: Ovid Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Rubric Capital Management LP (6.41%), Vanguard Group Inc. (3.66%), Stonepine Capital Management LLC (2.19%), BlackRock Inc. (1.64%), Dimensional Fund Advisors LP (0.06%) and Tower Research Capital LLC TRC (0.05%). Insiders that own company stock include Amit Rakhit, Jason Tardio and Jeremy M Levin.
View institutional ownership trends.
How do I buy shares of Ovid Therapeutics?: Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ovid Therapeutics' stock price today?: One share of OVID stock can currently be purchased for approximately $1.82.
How much money does Ovid Therapeutics make?: Ovid Therapeutics (NASDAQ:OVID) has a market capitalization of $128.25 million and generates $208.38 million in revenue each year. The company earns $122.83 million in net income (profit) each year or ($0.99) on an earnings per share basis.
How can I contact Ovid Therapeutics?: Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The official website for the company is www.ovidrx.com. The company can be reached via phone at (646) 661-7661 or via email at investors@ovidrx.com.

This page (NASDAQ:OVID) was last updated on 12/9/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial